The Filing Desk

Ironwood Pharmaceuticals vs Rigel Pharmaceuticals

Ironwood Pharmaceuticals IRWD · Rigel Pharmaceuticals RIGL · Pharmaceuticals

Ironwood Pharmaceuticals reported revenue of $296 million in fiscal 2025, about the same as Rigel Pharmaceuticals' $294 million in fiscal 2025. Ironwood Pharmaceuticals' revenue fell 15.7% in its latest year, and Rigel Pharmaceuticals' grew 64.2%. Ironwood Pharmaceuticals had an operating margin of 33.3%, against 42.6% at Rigel Pharmaceuticals.

Side by side

Ironwood PharmaceuticalsRigel Pharmaceuticals
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$296M$294M
Revenue growth−15.7%64.2%
Revenue growth a year, last 5 years−5.3%22.1%
Gross margin—93.3%
Operating margin33.3%42.6%
Net margin8.1%124.7%
Free cash flow$127M—
Free cash flow margin42.9%—
Return on capital—91.3%
Net debt to EBITDA—−0.8x
Dividends and buybacks$0M$0M
Change in diluted share count1.8%6.5%
Last close$4.83$44.46
P/E at the last close5.4×2.8×
Insider trades, last 12 months——
Piotroski F-score—7 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Ironwood PharmaceuticalsRigel Pharmaceuticals
Operating margin
Percent of revenue
Ironwood PharmaceuticalsRigel Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Ironwood PharmaceuticalsRigel Pharmaceuticals

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Ironwood Pharmaceuticals and Rigel Pharmaceuticals pages.